SBSyed Rizwan Ali Bokhari

Syed Rizwan Ali Bokhari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Syed Rizwan Ali Bokhari has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anti-neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis Secondary to Hydralazine: A Case Report

    by Ahmed Abdullah, Muhammad Saad Anwar, Maria Ijaz, Muhammad Sikandar Karim, Raquel Rosen, Syed Rizwan A Bokhari

    Hydralazine is a vasodilator used in the treatment of resistant hypertension. It is a safe and widely used antihypertensive medicine. Its common adverse effects include headache, rebound tachycardia, fluid retention, and angina. It is a rare cause of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with pulmonary and renal involvement. We report a case of a 74-year-old woman, with over eight years of use of hydralazine, who presented to the hospital with shortness of breath and cough. Blood work revealed deranged renal function with high creatinine levels. Serology workup was positive for anti-histone antibodies (AHA), anti-nuclear antibodies (ANA), myeloperoxidase (MPO) ANCA and proteinase-3 (PR-3) ANCA. Renal biopsy showed diffusely flattened tubular epithelium, focal micro vesicular degeneration, and focal loss of the brush border of the proximal tubular epithelium. Hydralazine was stopped and the patient was treated with corticosteroids, resulting in the resolution of her kidney injury.


  • Open Access

    Acquired Cystic Kidney Disease in ESRD Patients On Maintenance Hemodialysis at A Tertiary Care Dialysis Center.

    by Syed Rizwan Ali Bokhari, Maria Rizwan Bokhari, Maha N. Syed, Hafiz Ijaz Ahmad, Syed Arsalan Khalid, Zaman Khan Aseer, Ayesha Mehmood Malik, Faisal Akhtar

    Renal cysts are commonly observed in patients on maintenance hemodialysis (HD). The frequency of acquired cystic kidney disease (ACKD) is not known in our End-stage renal disease (ESRD) population. Methods: Seventy-Four ESRD patients on maintenance hemodialysis at Jinnah Hospital Dialysis center were assessed for the study. These patients underwent ultrasound examination by consultant radiologist for the presence of renal cysts. Results: Median duration on hemodialysis was four years (1-12 years). Cause of ESRD was Hypertension (63%) Diabetes mellitus (30%) and Obstructive uropathy (7%). Twenty-nine (40%) patients had hepatitis C infection. Sixty (85 %) patients were on thrice weekly, and 11 (15%) were on twiceweekly HD. Thirty-three (46%) patients had one renal cyst, 26 (37%) patients had 2-5 renal cysts, and 12 (17%) patients had more than five renal cysts bilaterally. Thirty-five (49%) Patients getting HD for less than three years had a median of three cysts (range 0-15), while remaining patients on HD for more than three years had a median number of 4.5 cysts (range 0-26). Nine (13%) on HD for less than one year had multiple renal cysts (1-4). None of these patients had evidence of extrarenal cysts, retroperitoneal or intrarenal hemorrhage. Conclusion: No significant correlation between ACKD and duration of hemodialysis was observed while a high frequency of renal cysts was seen earlier (within one year of HD). The reason may be the late initiation of HD at a much lower GFR, which is a routine in the developing countries .

  • Open Access

    Clinical and Etiological Spectrum of Hypokalemic Periodic Paralysis in a Tertiary Care Hospital in Pakistan

    by Zumar Sardar, Kh. Ahmad Furqan Waheed, M. Athar Javed, Faisal Akhtar, Syed Rizwan A Bokhari

    Hypokalemic periodic paralysis (HPP) is characterized by muscle weakness secondary to low serum potassium levels. It may be primary in origin or there may be secondary causes like thyrotoxic periodic paralysis, renal or suprarenal causes, or non-renal causes like gastroenteritis. To study the etiology, clinical manifestations, and outcome after therapy of patients with hypokalemic paralysis. The study was conducted from January 2016 to December 2016. Patients fulfilling the diagnostic criteria for hypokalemic paralysis, i.e., flaccid muscle weakness involving two or more limb muscles due to serum potassium < 3.5 mmol/L and with no objective sensory signs were included in the study. Relevant investigations were done. Those with other causes of flaccid weakness or on diuretic therapy were excluded from the study. Data was analyzed using SPSS Version 20.0 (IBM Corp., Armonk, NY). In our study, 14 patients out of a total of 18 (14/18, i.e., 77.78%) were male and 4/18 (22.22%) were female [Male: Female ratio: 3.5:1]. The mean age of onset of HPP in males (29.5±10.14 yrs.) was lesser than that of females (41±10.8 yrs.), but this difference was statistically not significant (p<0.066). In the entire sample there were 15/18 cases (83.33%) of primary and 3/18 (16.67%) cases of secondary HPP [2/3 had thyrotoxic periodic paralysis and 1/3 had gastroenteritis]. Furthermore, 12/18 patients (66.66%) had symmetrical weakness (five cases of paraparesis and all were male; seven cases of quadriparesis: six males and one female) and 6/18 (33.33%) had asymmetrical weakness (two paraparesis: one male, one female; four quadriparesis: two males, two females). Statistically, no significant difference (p<0.709) was seen in those with symmetrical versus those with asymmetrical weakness. In this study 7/18 (38.89%) cases had absent, 1/18 (5.55%) had diminished, and 10/18 (55.55%) cases had intact deep tendon reflexes. None of the cases had cranial, bulbar, or respiratory involvement. The mean serum potassium of sample was 3.18±0.5 standard deviation (SD). The reduction in serum potassium was moderate (2.5-3.5 mmol/L) in primary and severe (<2.5 mmol/L) in secondary HPP. Those with quadriparesis had severe hypokalemia with a mean serum potassium of 2.1 mmol/L. Only 3/18 patients had concomitant magnesium deficiency. Patients given intravenous potassium replacement (except one with moderate hypokalemia and given oral replacement) recovered dramatically. The mean recovery time was 38.6±20.3 hours. The recovery time in quadriparesis was about 24 hours and in paraparesis was 12 hours. Only one patient with thyrotoxic periodic paralysis (TPP) and with severe serum potassium deficiency (0.9 meq/L) died due to cardiac arrhythmia. No atypical presentation was seen. HPP has male preponderance. The age of onset of HPP is earlier in males than in females. Moreover, males are more prone to have symmetrical weakness. Asymmetrical weakness has almost an equal gender distribution. Primary hypokalemic paralysis is more frequent than secondary. Thyrotoxic periodic paralysis is the commonest cause of secondary periodic paralysis. The recovery time in quadriparesis is almost double the recovery time in paraparesis. Respiratory involvement is rare. HPP is an important differential in the diagnosis of acute flaccid muscle weakness. It should be promptly addressed to prevent recurrence of paralysis.


  • Open Access

    Cardiovascular Autonomic Neuropathy and its Association with Cardiovascular and All-cause Mortality in Patients with End-stage Renal Disease

    by Syed Rizwan A Bokhari, Faisal Inayat, Ali Jawa, Hafeez Ul Hasan Virk, Muhammad Awais, Nadeem Hussain, Ghias Ul Hassan, Hafiz Ijaz Ahmad, Hammad S. Chaudhry, Abdullah Adil, et al.

    End-stage renal disease frequently leads to increased cardiovascular mortality. Cardiovascular autonomic neuropathy (CAN) may be predictive of cardiac arrhythmias and sudden cardiac death in patients with end-stage renal disease. A total of 70 patients with end-stage renal disease were included in the study. The assessment of cardiac dysautonomia was based on the four standardized tests performed at the baseline and, again, at the end of the study. The criteria for CAN included at least two abnormal test results. Fifty of 70 patients completed the study and were followed-up after one year. Out of the 50 patients, 44 (88%) had CAN at baseline. Twelve (24%) patients died at the one-year follow-up. Sudden cardiac death was reported in seven out of 12 (58%) patients. All seven patients who died had high dysautonomia scores (three abnormal tests) at the baseline. There was a significantly higher percentage of patients with all four abnormal tests amongst patients who died of any cause (56% vs. 17%; RR 6.07, 95% CI 1.29-28.49; p-value 0.02) or due to sudden cardiac death (43% vs. 10.5%; RR 6.37, 95% CI 1.03-39.36; p-value 0.04). All five patients who did not have CAN at the baseline developed this abnormality on repeat testing after one year. The prevalence of CAN in patients with end-stage renal disease on maintenance hemodialysis was significantly higher. CAN was an independent predictor of all-cause and cardiovascular mortality, which highlights it as a risk stratification tool in patients with end-stage renal disease.